id: medication_formulation_type_to_medication_adherence_aud
name: Medication Formulation Type (Injectable vs Oral) â†’ Medication Adherence for
  Alcohol Use Disorder
from_node:
  node_id: medication_formulation_type
  node_name: Medication Formulation Type (Injectable vs Oral)
to_node:
  node_id: medication_adherence_aud
  node_name: Medication Adherence for Alcohol Use Disorder
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Injectable formulations (extended-release naltrexone) require less frequent
  dosing (monthly) compared to daily oral medications'
- 'Step 2: Reduced dosing frequency decreases barriers to consistent medication availability
  and use'
- 'Step 3: Healthcare system structures medication access around formulation type,
  with injectable requiring scheduled clinical visits that facilitate adherence monitoring'
- 'Step 4: Higher adherence rates for injectable formulations (54.6%) compared to
  oral formulations (41.3-49.8%) support treatment engagement'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: James R Walker et al. 2019. "Adherence Across FDA-Approved Medications
    for Alcohol Use Disorder in a Veterans Administration Population.." *Journal of
    studies on alcohol and drugs*. https://doi.org/10.15288/jsad.2019.80.572
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.683241'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: medication_type
  direction: strengthens
  strength: moderate
  description: Injectable naltrexone showed strongest adherence (54.6%) compared to
    disulfiram (41.3%), with significant difference (p=0.004)
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/medication_formulation_type_to_medication_adherence_aud.yaml
_category: healthcare_access
